Lingaiah, S., Morin-Papunen, L., Piltonen, T., Sundström-Poromaa, I., Stener-Victorin, E., & Tapanainen, J. S. (2019). Serum retinol-binding protein 4 levels in polycystic ovary syndrome. Endocrine Connections, 8(6), 709–717. https://doi.org/10.1530/ec-19-0116
Serum retinol-binding protein 4 levels in polycystic ovary syndrome
|Author:||Lingaiah, Shilpa1; Morin-Papunen, Laure1; Piltonen, Terhi1;|
1Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Centre, University of Oulu and Oulu University Hospital, Oulu, Finland
2Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
3Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
4Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019081324002
|Publish Date:|| 2019-08-13
Objective: Serum levels of retinol-binding protein 4 (RBP4), an adipokine thought to affect systemic insulin sensitivity, were compared between women with polycystic ovary syndrome (PCOS) and non-PCOS controls to evaluate the association of RBP4 with clinical, hormonal and metabolic parameters of PCOS.
Subjects and methods: Serum RBP4 levels were analysed in 278 women with PCOS (age range 18–57 years) and 191 non-PCOS controls (age 20–53 years) by enzyme-linked immunosorbent assay.
Results: Serum levels of RBP4 were increased in women with PCOS compared with control women in the whole population (45.1 ± 24.0 (s.d.) vs 33.5 ± 18.3 mg/L, P < 0.001). Age-stratified analysis showed that serum RBP4 levels were increased in women with PCOS aged ≤30 years compared with controls (47.7 ± 23.5 vs 27.1 ± 10.4 mg/L, P < 0.001), whereas no significant differences were seen in the other age groups. No significant correlations of RBP4 were seen with either steroids or indices of insulin resistance.
Conclusions: Although serum RBP4 levels were increased in younger women with PCOS compared with age-matched non-PCOS controls, RBP4 does not seem to be a good marker of insulin resistance or other metabolic derangements in women with PCOS.
|Pages:||709 - 717|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3123 Gynaecology and paediatrics
This work was supported by grants from the Sigrid Jusélius Foundation, Päivikki and Sakari Sohlberg Foundation, Medical Research Centre Oulu, Oulu University Hospital and the University of Oulu.
© 2019 The authors. Published by Bioscientifica Ltd. This work is licensed under a Creative Commons Attribution 4.0 International License.